Cara Therapeutics, Inc. (NASDAQ:CARA) CEO Derek T. Chalmers sold 16,000 shares of the stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $12.66, for a total value of $202,560.00. Following the transaction, the chief executive officer now owns 1,066,292 shares in the company, valued at approximately $13,499,256.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Cara Therapeutics, Inc. (NASDAQ:CARA) traded down $0.67 during midday trading on Friday, hitting $11.51. The stock had a trading volume of 438,755 shares, compared to its average volume of 835,692.

Cara Therapeutics (NASDAQ:CARA) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.03). During the same quarter last year, the firm posted ($0.42) earnings per share. analysts forecast that Cara Therapeutics, Inc. will post -1.72 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Derek T. Chalmers Sells 16,000 Shares of Cara Therapeutics, Inc. (CARA) Stock” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/11/03/derek-t-chalmers-sells-16000-shares-of-cara-therapeutics-inc-cara-stock.html.

Several large investors have recently bought and sold shares of the stock. State Street Corp increased its holdings in shares of Cara Therapeutics by 686.2% in the second quarter. State Street Corp now owns 3,245,043 shares of the biopharmaceutical company’s stock valued at $49,943,000 after purchasing an additional 2,832,304 shares during the last quarter. FMR LLC increased its holdings in shares of Cara Therapeutics by 27.7% in the second quarter. FMR LLC now owns 1,198,812 shares of the biopharmaceutical company’s stock valued at $18,450,000 after purchasing an additional 260,036 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Cara Therapeutics by 17.4% in the second quarter. Vanguard Group Inc. now owns 1,107,874 shares of the biopharmaceutical company’s stock valued at $17,050,000 after purchasing an additional 164,247 shares during the last quarter. Balyasny Asset Management LLC increased its holdings in shares of Cara Therapeutics by 376.3% in the second quarter. Balyasny Asset Management LLC now owns 525,000 shares of the biopharmaceutical company’s stock valued at $8,080,000 after purchasing an additional 715,000 shares during the last quarter. Finally, Morgan Stanley increased its holdings in shares of Cara Therapeutics by 360.3% in the first quarter. Morgan Stanley now owns 332,606 shares of the biopharmaceutical company’s stock valued at $6,117,000 after purchasing an additional 260,344 shares during the last quarter. 61.06% of the stock is owned by hedge funds and other institutional investors.

CARA has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded Cara Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a research report on Wednesday, August 30th. Scotiabank increased their price target on Cara Therapeutics from $31.00 to $31.50 and gave the stock an “outperform” rating in a research report on Tuesday, October 17th. BidaskClub downgraded Cara Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Cara Therapeutics in a research report on Friday, August 4th. Finally, ValuEngine downgraded Cara Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, September 27th. One analyst has rated the stock with a sell rating, four have issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. Cara Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $25.46.

About Cara Therapeutics

Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.

Receive News & Ratings for Cara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.